News

The updated ICH Q5A(R2) draft guidance has been released
The updated ICH Q5A(R2) draft guidance has been released

News ReleasePathoQuest, a leader in the development and provision of Next Generation Sequencing (NGS) testing services for the biopharmaceutical industry, is excited to announce that the updated ICH Q5A(R2) draft guidance for the “Viral Safety Evaluation of...

read more
PathoQuest Announce the Opening of its New U.S. Facility
PathoQuest Announce the Opening of its New U.S. Facility

Press ReleaseThe Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. MarketWayne, PA, and Paris, France – October 4, 2022 – PathoQuest, a leader in the development and provision of Next...

read more
PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors
PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors

Rainer Metzger works as a business professional in the Life Science and Pharmaceutical Industry. He has led numerous partnerships for co-development, commercialization, M&A and licensing. Rainer has been in leading positions in precision medicine, initiating and managing partnerships and services for clinical trials, co-development, and commercialization with QIAGEN, ROCHE, DANAHER and MEDICOVER establishing and running business with pharmaceutical companies. Rainer is acting as a board member for a series of Biotech companies in Europe and the US. He holds a Diploma in natural sciences and genetics and a PhD in Biology and Pharmacology from the University of Heidelberg.

read more

Click here to learn more about PathoQuest’s Biologics Genomic Service for biopharmaceutical companies.

Connect

 

EnglishFrenchGermanSpanish